A Phase 4 interventional study of Tamoxifen and Tamoxifen and Desvenlafaxine Succinate Sustained Release in Pharmacokinetics, sponsored by Pfizer. Completed at 2 sites in United States. Open to female participants aged 45 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-11-07.
Sponsored by Pfizer · Phase 4, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this study is to evaluate the effect of multiple doses of Desvenlafaxine SR on the pharmacokinetics of Tamoxifen and endoxifen when coadministered to healthy post-menopausal female subjects. This study will also evaluate the safety and tolerability of Desvenlafaxine SR and Tamoxifen when coadministered to healthy post-menopausal female subjects.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tamoxifen · Drug: Tamoxifen and Desvenlafaxine Succinate Sustained Release
Period 1-Tamoxifen 40mg on study day 1.
Period 2-Desvenlafaxine SR 100mg on days 1-28 with coadministration of Tamoxifen 40mg on day 7.
Tamoxifen Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Tamoxifen Alone and When Coadministered With DVS SR
Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞); measured as nanograms multiplied by hours divided by milliliters (ng\*hr/mL).
Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Endoxifen (Metabolite) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Endoxifen Alone and When Coadministered With DVS SR
Endoxifen is a metabolite of Tamoxifen. Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Tamoxifen Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR
Cmax measured as nanograms per milliliters (ng/mL).
Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Tamoxifen Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR
Time for maximum observed plasma concentration.
Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Tamoxifen Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR
Terminal half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Tamoxifen Apparent Clearance (CL/F) Following Tamoxifen Alone and When Coadministered With DVS SR
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood calculated as (Dose/AUCinf); measured as milliliters per minute (mL/min).
Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Tamoxifen Apparent Volume of Distribution (Vz/F) Following Tamoxifen Alone and When Coadministered With DVS SR
Calculated as Dose / (AUCinf \* kel); where kel=terminal phase rate constant.
Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Endoxifen (Metabolite) Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR
Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Endoxifen (Metabolite) Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR
Time for maximum observed plasma concentration.
Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Endoxifen (Metabolite) Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR
Terminal half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Endoxifen (Metabolite) Apparent Clearance (CL/F) Following Tamoxifen Alone and When Coadministered With DVS SR
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood calculated as (Dose/AUCinf); measured as milliliters per minute (mL/min).
Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Endoxifen (Metabolite) Apparent Volume of Distribution (Vz/F) Following Tamoxifen Alone and When Coadministered With DVS SR
Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
N-desmethyl-tamoxifen (Metabolite) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Tamoxifen Alone and When Coadministered With DVS SR
N-desmethyl-tamoxifen is a metabolite of Tamoxifen. Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
N-desmethyl-tamoxifen (Metabolite) Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR
Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
N-desmethyl-tamoxifen (Metabolite) Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR
Time for maximum observed plasma concentration.
Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
N-desmethyl-tamoxifen (Metabolite) Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR
Terminal half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
N-desmethyl-tamoxifen (Metabolite) Apparent Clearance (CL/F) Following Tamoxifen Alone and When Coadministered With DVS SR
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood calculated as (Dose/AUCinf); measured as milliliters per minute (mL/min).
Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
N-desmethyl-tamoxifen (Metabolite) Apparent Volume of Distribution (Vz/F) Following Tamoxifen Alone and When Coadministered With DVS SR
Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
4-hydroxy-tamoxifen (Metabolite) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Tamoxifen Alone and When Coadministered With DVS SR
4-hydroxy-tamoxifen is a metabolite of Tamoxifen. Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
4-hydroxy-tamoxifen (Metabolite) Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR
Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
4-hydroxy-tamoxifen (Metabolite) Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR
Time for maximum observed plasma concentration.
Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
4-hydroxy-tamoxifen (Metabolite) Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR
Terminal half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
4-hydroxy-tamoxifen (Metabolite) Apparent Clearance (CL/F) Following Tamoxifen Alone and When Coadministered With DVS SR
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood calculated as (Dose/AUCinf); measured as milliliters per minute (mL/min).
Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
4-hydroxy-tamoxifen (Metabolite) Apparent Volume of Distribution (Vz/F) Following Tamoxifen Alone and When Coadministered With DVS SR
Time frame: Period 1 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing; Period 2 / Day 1 and Day 7: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; 0 hour on Day 8, 9, 10, 12, 14, 16, 18, 20, 23, 26 and 29.
Plasma Tamoxifen Concentration Versus Time Summary: Tamoxifen Alone and When Coadministered With DVS SR
Summary statistics were to be calculated by setting concentration values below the lower limit of quantification (LLQ = 0.250 ng/mL) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) = 0.
Time frame: Period 1 / Day 1 and Period 2 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing
Plasma Endoxifen (Metabolite) Concentration Versus Time Summary: Tamoxifen Alone and When Coadministered With DVS SR
Summary statistics were to be calculated by setting concentration values below the lower limit of quantification (LLQ = 0.100 ng/mL) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) = 0.
Time frame: Period 1 / Day 1 and Period 2 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing
Plasma N-desmethyl-tamoxifen (Metabolite) Concentration Versus Time Summary: Tamoxifen Alone and When Coadministered With DVS SR
Summary statistics were to be calculated by setting concentration values below the lower limit of quantification (LLQ = 0.250 ng/mL) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) = 0.
Time frame: Period 1 / Day 1 and Period 2 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing
Plasma 4-hydroxy-tamoxifen (Metabolite) Concentration Versus Time Summary: Tamoxifen Alone and When Coadministered With DVS SR
Summary statistics were to be calculated by setting concentration values below the lower limit of quantification (LLQ = 0.100 ng/mL) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) = 0.
Time frame: Period 1 / Day 1 and Period 2 / Day 1: 0, 0.5, 1, 2, 3, 4, 6, 8, 12,16, 24, 48, 72, 120, 168, 216, 264, 312, 384, 456, and 528 hours after dosing
| Milestone | Tamoxifen 40 mg, Tamoxifen 40 mg + DVS SR 100 mg |
|---|---|
| Started | 30 |
| Completed | 29 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
| Milestone | Tamoxifen 40 mg, Tamoxifen 40 mg + DVS SR 100 mg |
|---|---|
| Started | 29 |
| Completed | 28 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞); measured as nanograms multiplied by hours divided by milliliters (ng\*hr/mL).
| ng*hr/mL | Tamoxifen 40 mg (Period 1) | Tamoxifen 40 mg + DVS SR 100 mg (Period 2) |
|---|---|---|
| Tamoxifen Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Tamoxifen Alone and When Coadministered With DVS SR | 5751 ± 1540.1 | 5888 ± 1905.5 |
Endoxifen is a metabolite of Tamoxifen. Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
| ng*hr/mL | Tamoxifen 40 mg (Period 1) | Tamoxifen 40 mg + DVS SR 100 mg (Period 2) |
|---|---|---|
| Endoxifen (Metabolite) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Endoxifen Alone and When Coadministered With DVS SR | 677.7 ± 200.42 | 505.6 ± 220.87 |
Cmax measured as nanograms per milliliters (ng/mL).
| ng/mL | Tamoxifen 40 mg (Period 1) | Tamoxifen 40 mg + DVS SR 100 mg (Period 2) |
|---|---|---|
| Tamoxifen Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR | 70.58 ± 16.310 | 70.33 ± 14.484 |
Time for maximum observed plasma concentration.
| hours | Tamoxifen 40 mg (Period 1) | Tamoxifen 40 mg + DVS SR 100 mg (Period 2) |
|---|---|---|
| Tamoxifen Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR | 4.00 (3.00 to 8.00) | 4.00 (3.00 to 8.00) |
Terminal half-life is the time measured for the plasma concentration to decrease by one half.
| hours | Tamoxifen 40 mg (Period 1) | Tamoxifen 40 mg + DVS SR 100 mg (Period 2) |
|---|---|---|
| Tamoxifen Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR | 250.5 ± 44.410 | 242.3 ± 51.851 |
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood calculated as (Dose/AUCinf); measured as milliliters per minute (mL/min).
| mL/min | Tamoxifen 40 mg (Period 1) | Tamoxifen 40 mg + DVS SR 100 mg (Period 2) |
|---|---|---|
| Tamoxifen Apparent Clearance (CL/F) Following Tamoxifen Alone and When Coadministered With DVS SR | 115.9 ± 34.544 | 113.2 ± 44.545 |
Calculated as Dose / (AUCinf \* kel); where kel=terminal phase rate constant.
| liters | Tamoxifen 40 mg (Period 1) | Tamoxifen 40 mg + DVS SR 100 mg (Period 2) |
|---|---|---|
| Tamoxifen Apparent Volume of Distribution (Vz/F) Following Tamoxifen Alone and When Coadministered With DVS SR | 2474 ± 461.71 | 2321 ± 419.76 |
| ng/mL | Tamoxifen 40 mg (Period 1) | Tamoxifen 40 mg + DVS SR 100 mg (Period 2) |
|---|---|---|
| Endoxifen (Metabolite) Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR | 1.077 ± 0.4528 | 1.226 ± 0.4956 |
Time for maximum observed plasma concentration.
| hours | Tamoxifen 40 mg (Period 1) | Tamoxifen 40 mg + DVS SR 100 mg (Period 2) |
|---|---|---|
| Endoxifen (Metabolite) Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR | 216 (47.9 to 312) | 120 (47.9 to 384) |
Terminal half-life is the time measured for the plasma concentration to decrease by one half.
| hours | Tamoxifen 40 mg (Period 1) | Tamoxifen 40 mg + DVS SR 100 mg (Period 2) |
|---|---|---|
| Endoxifen (Metabolite) Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR | 207.5 ± 43.59 | 232.5 ± 56.719 |
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood calculated as (Dose/AUCinf); measured as milliliters per minute (mL/min).
No measurements were reported for this outcome.
No measurements were reported for this outcome.
N-desmethyl-tamoxifen is a metabolite of Tamoxifen. Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
| ng*hr/mL | Tamoxifen 40 mg (Period 1) | Tamoxifen 40 mg + DVS SR 100 mg (Period 2) |
|---|---|---|
| N-desmethyl-tamoxifen (Metabolite) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Tamoxifen Alone and When Coadministered With DVS SR | 8187 ± 1688.0 | 9329 ± 2236.8 |
| ng/mL | Tamoxifen 40 mg (Period 1) | Tamoxifen 40 mg + DVS SR 100 mg (Period 2) |
|---|---|---|
| N-desmethyl-tamoxifen (Metabolite) Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR | 18.30 ± 3.7576 | 24.42 ± 4.3709 |
Time for maximum observed plasma concentration.
| hours | Tamoxifen 40 mg (Period 1) | Tamoxifen 40 mg + DVS SR 100 mg (Period 2) |
|---|---|---|
| N-desmethyl-tamoxifen (Metabolite) Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR | 35.9 (4.00 to 312) | 47.9 (4.00 to 168) |
Terminal half-life is the time measured for the plasma concentration to decrease by one half.
| hours | Tamoxifen 40 mg (Period 1) | Tamoxifen 40 mg + DVS SR 100 mg (Period 2) |
|---|---|---|
| N-desmethyl-tamoxifen (Metabolite) Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR | 256.0 ± 24.042 | 265.6 ± 32.082 |
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood calculated as (Dose/AUCinf); measured as milliliters per minute (mL/min).
No measurements were reported for this outcome.
No measurements were reported for this outcome.
4-hydroxy-tamoxifen is a metabolite of Tamoxifen. Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
| ng*hr/mL | Tamoxifen 40 mg (Period 1) | Tamoxifen 40 mg + DVS SR 100 mg (Period 2) |
|---|---|---|
| 4-hydroxy-tamoxifen (Metabolite) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Tamoxifen Alone and When Coadministered With DVS SR | 117.5 ± 55.433 | 133.9 ± 62.784 |
| ng/mL | Tamoxifen 40 mg (Period 1) | Tamoxifen 40 mg + DVS SR 100 mg (Period 2) |
|---|---|---|
| 4-hydroxy-tamoxifen (Metabolite) Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR | 0.6716 ± 0.1649 | 0.7247 ± 0.1799 |
Time for maximum observed plasma concentration.
| hours | Tamoxifen 40 mg (Period 1) | Tamoxifen 40 mg + DVS SR 100 mg (Period 2) |
|---|---|---|
| 4-hydroxy-tamoxifen (Metabolite) Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR | 6.00 (4.00 to 12.00) | 6.00 (3.00 to 23.9) |
Terminal half-life is the time measured for the plasma concentration to decrease by one half.
| hours | Tamoxifen 40 mg (Period 1) | Tamoxifen 40 mg + DVS SR 100 mg (Period 2) |
|---|---|---|
| 4-hydroxy-tamoxifen (Metabolite) Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR | 165.2 ± 49.699 | 177.0 ± 54.525 |
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood calculated as (Dose/AUCinf); measured as milliliters per minute (mL/min).
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Summary statistics were to be calculated by setting concentration values below the lower limit of quantification (LLQ = 0.250 ng/mL) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) = 0.
| ng/mL | Tamoxifen 40 mg (Period 1) | Tamoxifen 40 mg + DVS SR 100 mg (Period 2) |
|---|---|---|
| 0 hour | NA (NA to NA) | 1.300 (0.293 to 4.66) |
| 0.5 hour post dose | 1.875 (0.000 to 10.3) | 4.650 (1.70 to 19.1) |
| 1 hour post dose | 11.45 (0.769 to 36.1) | 13.90 (3.31 to 47.8) |
| 2 hours post dose | 37.20 (2.55 to 74.7) | 33.60 (11.0 to 75.2) |
| 3 hours post dose | 54.50 (6.57 to 100) | 55.60 (17.0 to 99.4) |
| 4 hours post dose | 68.25 (26.9 to 95.7) | 72.20 (26.6 to 90.7) |
| 6 hours post dose | 58.95 (40.1 to 89.3) | 60.90 (38.5 to 90.8) |
| 8 hours post dose | 54.75 (32.2 to 77.8) | 56.10 (33.6 to 73.9) |
| 12 hours post dose | 40.40 (21.5 to 61.0) | 35.30 (22.8 to 51.7) |
| 16 hours post dose | 27.30 (16.4 to 41.6) | 26.20 (12.9 to 39.5) |
| 24 hours post dose | 24.50 (16.9 to 30.9) | 25.50 (12.0 to 39.3) |
| 48 hours post dose | 15.40 (7.86 to 22.1) | 16.20 (8.36 to 27.1) |
| 72 hours post dose | 12.55 (7.28 to 18.8) | 12.60 (7.50 to 27.7) |
| 120 hours post dose | 10.55 (4.78 to 16.3) | 11.60 (5.85 to 21.0) |
| 168 hours post dose | 9.120 (3.75 to 13.2) | 9.930 (4.83 to 14.9) |
| 216 hours post dose | 7.555 (4.10 to 14.0) | 8.150 (3.32 to 17.9) |
| 264 hours post dose | 7.575 (3.25 to 12.0) | 7.270 (2.75 to 13.5) |
| 312 hours post dose | 6.445 (2.58 to 12.7) | 6.920 (2.85 to 14.3) |
| 384 hours post dose | 5.180 (2.18 to 10.4) | 5.600 (1.83 to 12.7) |
| 456 hours post dose | 4.300 (1.65 to 8.75) | 4.330 (1.65 to 9.13) |
| 528 hours post dose | 3.560 (1.39 to 8.14) | 4.160 (1.03 to 10.9) |
Summary statistics were to be calculated by setting concentration values below the lower limit of quantification (LLQ = 0.100 ng/mL) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) = 0.
| ng/mL | Tamoxifen 40 mg (Period 1) | Tamoxifen 40 mg + DVS SR 100 mg (Period 2) |
|---|---|---|
| 0 hour | NA (NA to NA) | 0.2900 (0.000 to 0.799) |
| 0.5 hour post dose | NA (NA to NA) | 0.3370 (0.000 to 0.792) |
| 1 hour post dose | NA (NA to NA) | 0.3430 (0.000 to 1.03) |
| 2 hours post dose | 0.0000 (0.000 to 0.126) | 0.4100 (0.102 to 1.15) |
| 3 hours post dose | 0.0000 (0.000 to 0.275) | 0.5020 (0.000 to 1.14) |
| 4 hours post dose | 0.1760 (0.000 to 0.590) | 0.6350 (0.119 to 1.26) |
| 6 hours post dose | 0.2485 (0.000 to 0.516) | 0.5870 (0.000 to 1.00) |
| 8 hours post dose | 0.2895 (0.102 to 0.624) | 0.7310 (0.149 to 1.39) |
| 12 hours post dose | 0.4470 (0.116 to 0.884) | 0.7310 (0.146 to 1.39) |
| 16 hours post dose | 0.4330 (0.111 to 0.818) | 0.7130 (0.120 to 1.46) |
| 24 hours post dose | 0.6215 (0.162 to 1.05) | 0.9900 (0.203 to 1.47) |
| 48 hours post dose | 0.9065 (0.150 to 1.40) | 1.180 (0.270 to 2.12) |
| 72 hours post dose | 0.9740 (0.178 to 1.54) | 1.180 (0.208 to 1.83) |
| 120 hours post dose | 1.095 (0.135 to 1.89) | 1.240 (0.287 to 2.13) |
| 168 hours post dose | 1.120 (0.128 to 1.97) | 1.140 (0.169 to 2.23) |
| 216 hours post dose | 1.120 (0.149 to 1.78) | 1.080 (0.193 to 1.80) |
| 264 hours post dose | 1.145 (0.166 to 1.57) | 1.160 (0.168 to 1.94) |
| 312 hours post dose | 1.035 (0.148 to 1.69) | 0.9760 (0.157 to 1.86) |
| 384 hours post dose | 0.8560 (0.169 to 1.50) | 0.9470 (0.121 to 1.61) |
| 456 hours post dose | 0.7060 (0.104 to 1.51) | 0.9150 (0.119 to 1.37) |
| 528 hours post dose | 0.6210 (0.000 to 1.23) | 0.7040 (0.000 to 1.47) |
Summary statistics were to be calculated by setting concentration values below the lower limit of quantification (LLQ = 0.250 ng/mL) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) = 0.
| ng/mL | Tamoxifen 40 mg (Period 1) | Tamoxifen 40 mg + DVS SR 100 mg (Period 2) |
|---|---|---|
| 0 hour | NA (NA to NA) | 3.600 (1.22 to 8.84) |
| 0.5 hour post dose | 0.0000 (0.000 to 0.465) | 4.120 (1.97 to 11.2) |
| 1 hour post dose | 0.8050 (0.000 to 3.34) | 5.650 (2.64 to 12.4) |
| 2 hours post dose | 4.210 (0.310 to 9.46) | 9.770 (4.51 to 16.7) |
| 3 hours post dose | 9.440 (1.03 to 20.2) | 14.80 (6.30 to 26.4) |
| 4 hours post dose | 12.55 (2.67 to 20.7) | 18.70 (9.09 to 29.9) |
| 6 hours post dose | 14.10 (7.61 to 23.3) | 19.30 (11.8 to 26.1) |
| 8 hours post dose | 14.90 (9.97 to 23.5) | 20.40 (14.3 to 30.3) |
| 12 hours post dose | 16.10 (10.8 to 26.8) | 19.00 (11.1 to 25.7) |
| 16 hours post dose | 14.55 (9.14 to 20.1) | 18.40 (11.6 to 35.1) |
| 24 hours post dose | 16.90 (8.64 to 23.3) | 21.90 (12.7 to 32.4) |
| 48 hours post dose | 16.45 (9.49 to 23.3) | 24.00 (13.3 to 34.9) |
| 72 hours post dose | 16.45 (8.01 to 21.8) | 19.80 (13.9 to 31.5) |
| 120 hours post dose | 15.10 (8.26 to 22.9) | 19.80 (15.0 to 31.4) |
| 168 hours post dose | 14.40 (8.04 to 26.1) | 16.80 (12.7 to 26.3) |
| 216 hours post dose | 13.50 (7.75 to 19.6) | 15.60 (8.60 to 24.3) |
| 264 hours post dose | 12.65 (8.13 to 17.6) | 15.40 (5.80 to 22.5) |
| 312 hours post dose | 11.40 (6.99 to 18.0) | 14.40 (8.39 to 20.6) |
| 384 hours post dose | 10.15 (6.46 to 15.5) | 13.10 (6.86 to 19.7) |
| 456 hours post dose | 8.730 (5.35 to 14.2) | 10.50 (3.24 to 16.3) |
| 528 hours post dose | 8.730 (4.69 to 13.0) | 10.40 (4.36 to 21.7) |
Summary statistics were to be calculated by setting concentration values below the lower limit of quantification (LLQ = 0.100 ng/mL) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) = 0.
| ng/mL | Tamoxifen 40 mg (Period 1) | Tamoxifen 40 mg + DVS SR 100 mg (Period 2) |
|---|---|---|
| 0 hour | NA (NA to NA) | 0.0000 (0.000 to 0.130) |
| 0.5 hour post dose | NA (NA to NA) | 0.0000 (0.000 to 0.171) |
| 1 hour post dose | NA (NA to NA) | 0.0000 (0.000 to 0.321) |
| 2 hours post dose | 0.2060 (0.000 to 0.431) | 0.2030 (0.000 to 0.633) |
| 3 hours post dose | 0.4335 (0.000 to 0.811) | 0.3960 (0.136 to 1.00) |
| 4 hours post dose | 0.5900 (0.101 to 1.03) | 0.6420 (0.232 to 1.13) |
| 6 hours post dose | 0.6145 (0.346 to 0.889) | 0.7060 (0.340 to 0.985) |
| 8 hours post dose | 0.6290 (0.307 to 0.985) | 0.7100 (0.408 to 1.06) |
| 12 hours post dose | 0.5910 (0.312 to 0.966) | 0.5860 (0.354 to 1.07) |
| 16 hours post dose | 0.4920 (0.322 to 0.887) | 0.5640 (0.308 to 0.947) |
| 24 hours post dose | 0.5395 (0.329 to 0.930) | 0.5780 (0.300 to 1.02) |
| 48 hours post dose | 0.4925 (0.233 to 0.931) | 0.4910 (0.235 to 1.12) |
| 72 hours post dose | 0.3795 (0.174 to 0.717) | 0.4010 (0.200 to 0.903) |
| 120 hours post dose | 0.2845 (0.102 to 0.627) | 0.2920 (0.171 to 0.745) |
| 168 hours post dose | 0.2180 (0.000 to 0.525) | 0.2270 (0.107 to 0.548) |
| 216 hours post dose | 0.1840 (0.000 to 0.435) | 0.1870 (0.000 to 0.423) |
| 264 hours post dose | 0.1590 (0.000 to 0.361) | 0.1600 (0.000 to 0.367) |
| 312 hours post dose | 0.1315 (0.000 to 0.338) | 0.1380 (0.000 to 0.323) |
| 384 hours post dose | 0.1125 (0.000 to 0.280) | 0.1180 (0.000 to 0.286) |
| 456 hours post dose | 0.0000 (0.000 to 0.283) | 0.0000 (0.000 to 0.208) |
| 528 hours post dose | 0.0000 (0.000 to 0.230) | 0.0000 (0.000 to 0.296) |
Collected over Baseline up to Day 36 (follow-up telephone visit). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tamoxifen 40 mg (Period 1) | — | 1/30 (3.3%) | 11/30 (36.7%) |
| DVS SR 100 mg (Period 2) | — | 0/29 (0%) | 17/29 (58.6%) |
| Tamoxifen 40 mg + DVS SR 100 mg (Period 2) | — | 0/29 (0%) | 24/29 (82.8%) |
| Event | Tamoxifen 40 mg (Period 1) | DVS SR 100 mg (Period 2) | Tamoxifen 40 mg + DVS SR 100 mg (Period 2) |
|---|---|---|---|
| CholecystitisHepatobiliary disorders | 1/30 | 0/29 | 0/29 |
| CholelithiasisHepatobiliary disorders | 1/30 | 0/29 | 0/29 |
| Event | Tamoxifen 40 mg (Period 1) | DVS SR 100 mg (Period 2) | Tamoxifen 40 mg + DVS SR 100 mg (Period 2) |
|---|---|---|---|
| HeadacheNervous system disorders | 1/30 | 1/29 | 9/29 |
| InsomniaPsychiatric disorders | 0/30 | 2/29 | 8/29 |
| PalpitationsCardiac disorders | 0/30 | 0/29 | 7/29 |
| ConstipationGastrointestinal disorders | 2/30 | 6/29 | 3/29 |
| NauseaGastrointestinal disorders | 0/30 | 4/29 | 2/29 |
| Upper respiratory tract infectionInfections and infestations | 0/30 | 0/29 | 4/29 |
| Abdominal painGastrointestinal disorders | 0/30 | 0/29 | 3/29 |
| Dry mouthGastrointestinal disorders | 0/30 | 1/29 | 3/29 |
| DyspepsiaGastrointestinal disorders | 0/30 | 2/29 | 3/29 |
| ToothacheGastrointestinal disorders | 0/30 | 0/29 | 3/29 |
| Age, Customized(participants) | Tamoxifen 40 mg, Tamoxifen 40 mg + DVS SR 100 mg |
|---|---|
| 45 to 64 years | 27 |
| ≥65 years | 3 |
| Sex/Gender, Customized(participants) | Tamoxifen 40 mg, Tamoxifen 40 mg + DVS SR 100 mg |
|---|---|
| Number | 30 |
The record gives a start of Aug 2010, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2011, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tamoxifen